The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
Open accessAbstract
Purpose: The National Surgical Adjuvant Breast and Bowel Project C-08 trial was designed to investigate the safety and efficacy of adding bevacizumab to modified FOLFOX6 (mFOLFOX6; ie, infusional/bolus fluorouracil, leucovorin, and oxaliplatin) for the adjuvant treatment of patients with stages II to III colon cancer. Methods: Patients received mFOLFOX6 every 2 weeks for 26 weeks alone or modified as FOLFOX6 + bevacizumab (5 mg/kg every 2 weeks for 52 weeks [ie, experimental group]). The primary end point was disease-free survival (DFS). Results: Among 2,672 analyzed patients, demographic factors were well balanced by treatment. With a median follow-up of 35.6 months, the addition of bevacizumab to mFOLFOX6 did not result in an overall significant increase in DFS (hazard ratio [HR], 0.89; 95% CI, 0.76 to 1.04; P = .15). The point estimates for 3-year DFS for the overall population were 77.4% and 75.5% for the experimental and control arms, respectively. For patients with stages II and III diseases, these same estimates were 87.4% and 84.7%, respectively, for stage II and 74.2% and 72.4%, respectively, for stage III. Exploratory analyses found that the effect of bevacizumab on DFS was different before and after a 15-month landmark (time-by-treatment interaction P value < .0001). Bevacizumab had a strong effect before the landmark (HR, 0.61; 95% CI, 0.48 to 0.78; P < .001) but no significant effect after (HR, 1.22; 95% CI, 0.98 to 1.52; P = .076). Conclusion: Bevacizumab for 1 year with mFOLFOX6 does not significantly prolong DFS in stages II and III colon cancer. However, a significant but transient effect during bevacizumab exposure was observed in the experimental arm. We postulate that this observation reflects a biologic effect during bevacizumab exposure. Given the lack of improvement in DFS, the use of bevacizumab cannot be recommended for use in the adjuvant treatment of patients with colon cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Self-citationEvaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
On the Interpretation of χ 2 from Contingency Tables, and the Calculation of P
Fisher, R. A. (1922) · Journal of the Royal Statistical Society · doi:10.2307/2340521 · Cited by 2,953
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Cited by
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Labianca, R., Nordlinger, B., Beretta, G. D., Mosconi, S., Mandalà, M., Cervantes, A., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt354 · Cited by 1,404
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Argilés, G., Tabernero, J., Labianca, R., Hochhauser, D., Salazar, R., Iveson, T., Laurent-Puig, P., Quirke, P., Yoshino, T., Taieb, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.022 · Cited by 1,375
Steeg, P. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.25 · Cited by 1,363
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y.-J., Cooper, H. S., Deming, D., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,330
Duration of adjuvant chemotherapy for stage III colon cancer
Grothey, A., Sobrero, A. F., Shields, A. F., Yoshino, T., Paul, J., Taieb, J., Souglakos, J., Shi, Q., Kerr, R., Labianca, R., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713709 · Cited by 1,092
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
Early‐onset colorectal cancer in young individuals
Mauri, G., Sartore‐Bianchi, A., Russo, A., Marsoni, S., Bardelli, A., & Siena, S. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12417 · Cited by 634
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 591
Adam, R., De Gramont, A., Figueras, J., Guthrie, A., Kokudo, N., Kunstlinger, F., Loyer, E., Poston, G., Rougier, P., Rubbia-Brandt, L., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0121 · Cited by 583
HCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 564
de Gramont, A., Van Cutsem, E., Schmoll, H.-J., Tabernero, J., Clarke, S., Moore, M. J., Cunningham, D., Cartwright, T. H., Hecht, J. R., Rivera, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70509-0 · Cited by 529
Kuczynski, E. A., Vermeulen, P. B., Pezzella, F., Kerbel, R. S., & Reynolds, A. R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0181-9 · Cited by 446
Cameron, D., Brown, J., Dent, R., Jackisch, C., Mackey, J., Pivot, X., Steger, G. G., Suter, T. M., Toi, M., Parmar, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70335-8 · Cited by 432
Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer
Kawakami, H., Zaanan, A., & Sinicrope, F. A. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0348-2 · Cited by 418
Schrag, D., Weiser, M. R., Goodman, K. A., Gon̈en, M., Hollywood, E., Cercek, A., Reidy-Lagunes, D. L., Gollub, M. J., Shia, J., Guillem, J. G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.7904 · Cited by 414
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Haibe, Y., Kreidieh, M., El Hajj, H., Khalifeh, I., Mukherji, D., Temraz, S., & Shamseddine, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00221 · Cited by 396
CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
Duda, D. G., Kozin, S. V., Kirkpatrick, N. D., Xu, L., Fukumura, D., & Jain, R. K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2636 · Cited by 395
A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer
Gustavsson, B., Carlsson, G., Machover, D., Petrelli, N., Roth, A., Schmoll, H.-J., Tveit, K.-M., & Gibson, F. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.11.002 · Cited by 381
Self-citationColon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Adam, M., Chang, G., Chen, Y.-J., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D., Garrido-Laguna, I., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0029 · Cited by 371
Vogel, J. D., Eskicioglu, C., Weiser, M. R., Feingold, D. L., & Steele, S. R. (2017) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000926 · Cited by 342
Gavin, P. G., Colangelo, L. H., Fumagalli, D., Tanaka, N., Remillard, M. Y., Yothers, G., Kim, C., Taniyama, Y., Kim, S. I., Choi, H. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0605 · Cited by 320
Self-citationCancer prevention by targeting angiogenesis
Albini, A., Tosetti, F., Li, V. W., Noonan, D. M., & Li, W. W. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.120 · Cited by 306
Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers
Olejarz, W., Kubiak-Tomaszewska, G., Chrzanowska, A., & Lorenc, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165840 · Cited by 299
Nilsson, P. J., van Etten, B., Hospers, G. A., Påhlman, L., van de Velde, C. J., Beets-Tan, R. G., Blomqvist, L., Beukema, J. C., Kapiteijn, E., Marijnen, C. A., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-279 · Cited by 293
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?
De Bock, K., Mazzone, M., & Carmeliet, P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.83 · Cited by 293
Taieb, J., Tabernero, J., Mini, E., Subtil, F., Folprecht, G., Van Laethem, J.-L., Thaler, J., Bridgewater, J., Petersen, L. N., Blons, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70227-x · Cited by 291
Cunningham, D., Stenning, S. P., Smyth, E. C., Okines, A. F., Allum, W. H., Rowley, S., Stevenson, L., Grabsch, H. I., Alderson, D., Crosby, T., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30043-8 · Cited by 289
Hack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598877 · Cited by 286
McCleary, N. J., Meyerhardt, J. A., Green, E., Yothers, G., de Gramont, A., Van Cutsem, E., O'Connell, M., Twelves, C. J., Saltz, L. B., Haller, D. G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6638 · Cited by 271
Self-citationSanoff, H. K., Carpenter, W. R., Stürmer, T., Goldberg, R. M., Martin, C. F., Fine, J. P., McCleary, N. J., Meyerhardt, J. A., Niland, J., Kahn, K. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.1140 · Cited by 271
Self-citationControlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3366 · Cited by 264
Anti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0081 · Cited by 201
Srivastava, K., Hu, J., Korn, C., Savant, S., Teichert, M., Kapel, S. S., Jugold, M., Besemfelder, E., Thomas, M., Pasparakis, M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.11.005 · Cited by 140
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.
Pogue-Geile, K., Yothers, G., Taniyama, Y., Tanaka, N., Gavin, P., Colangelo, L., Blackmon, N., Lipchik, C., Kim, S. R., Sharif, S., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt140 · Cited by 61
Self-citationAflibercept in the Treatment of Metastatic Colorectal Cancer
Wang, T.-F., & Lockhart, A. C. (2012) · Clinical Medicine Insights: Oncology · doi:10.4137/cmo.s7432 · Cited by 44
Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data
Hansen, T. F., Qvortrup, C., & Pfeiffer, P. (2021) · Cancers · doi:10.3390/cancers13051031 · Cited by 43
Bender, U., Rho, Y. S., Barrera, I., Aghajanyan, S., Acoba, J., & Kavan, P. (2019) · Current Oncology · doi:10.3747/co.26.5605 · Cited by 36
Zunder, S. M., van Pelt, G. W., Gelderblom, H. J., Mancao, C., Putter, H., Tollenaar, R. A., & Mesker, W. E. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0083-0 · Cited by 36
Wen, C., Chen, J., Zhang, D., Wang, H., Che, J., Qin, Q., He, L., Cai, Z., Lin, M., Lou, Q., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.09.007 · Cited by 35
Liu, B., Polack, M., Coudray, N., Claudio Quiros, A., Sakellaropoulos, T., Le, H., Karimkhan, A., Crobach, A. S. L. P., van Krieken, J. H. J. M., Yuan, K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57541-y · Cited by 25
“…of bevacizumab and its adverse effect in non-metastatic colon cancer, as also proven by a predecessing clinical trial, the NSABP protocol C-08 trial 63 , we decided to primarily validate OS prediction, trained in the TCGA-COAD, within the control group who only received FOLFOX-4 (without…”
Boyne, D. J., O'Sullivan, D. E., Heer, E. V., Hilsden, R. J., Sajobi, T. T., Cheung, W. Y., Brenner, D. R., & Friedenreich, C. M. (2020) · Cancer Medicine · doi:10.1002/cam4.2843 · Cited by 11
Zunder, S., van der Wilk, P., Gelderblom, H., Dekker, T., Mancao, C., Kiialainen, A., Putter, H., Tollenaar, R., & Mesker, W. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00449-9 · Cited by 9
Metadata
- Authors
- Allegra, C. J., Yothers, G., O'Connell, M. J., Sharif, S., Petrelli, N. J., Colangelo, L. H., Atkins, J. N., Seay, T. E., Fehrenbacher, L., Goldberg, R. M., O'Reilly, S., Chu, L., Azar, C. A., Lopa, S., & Wolmark, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-01-01
- Volume
- 29
- Issue
- 1
- Pages
- 11-16
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2125857654
- Cited by
- 593
- References
- 24
- FWCI
- 36.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.